4D Molecular Therapeutics, Inc. Purchase Obligation
4D Molecular Therapeutics, Inc. (FDMT) had Purchase Obligation of $4.90 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:PurchaseObligation · last filed 2026-08-13
- 2026-06-30: Purchase Obligation $4.90M.
- 2026-03-31: Purchase Obligation $7.00M.
- 2025-12-31: Purchase Obligation $4.00M.
| Period end | Purchase Obligation |
|---|---|
| 2026-06-30 | $4.90M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $7.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $4.00M 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |